BenzingaOctober 7, 2026 at 6:15 AM NY20 Days Ago
Barclays Maintains Overweight on Elevance Health, Raises Price Target to $469
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $457 to $469.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
